Abstract:AlphaFold2 (AF2) and RoseTTaFold (RF) have revolutionized structural biology, serving as highly reliable and effective methods for predicting protein structures. This article explores their impact and limitations, focusing on their integration into experimental pipelines and their application in diverse protein classes, including membrane proteins, intrinsically disordered proteins (IDPs), and oligomers. In experimental pipelines, AF2 models help X-ray crystallography in resolving the phase problem, while complementarity with mass spectrometry and NMR data enhances structure determination and protein flexibility prediction. Predicting the structure of membrane proteins remains challenging for both AF2 and RF due to difficulties in capturing conformational ensembles and interactions with the membrane. Improvements in incorporating membrane-specific features and predicting the structural effect of mutations are crucial. For intrinsically disordered proteins, AF2's confidence score (pLDDT) serves as a competitive disorder predictor, but integrative approaches including molecular dynamics (MD) simulations or hydrophobic cluster analyses are advocated for accurate dynamics representation. AF2 and RF show promising results for oligomeric models, outperforming traditional docking methods, with AlphaFold-Multimer showing improved performance. However, some caveats remain in particular for membrane proteins. Real-life examples demonstrate AF2's predictive capabilities in unknown protein structures, but models should be evaluated for their agreement with experimental data. Furthermore, AF2 models can be used complementarily with MD simulations. In this Perspective, we propose a "wish list" for improving deep-learning-based protein folding prediction models, including using experimental data as constraints and modifying models with binding partners or post-translational modifications. Additionally, a meta-tool for ranking and suggesting composite models is suggested, driving future advancements in this rapidly evolving field.

Structural modeling of antibody variable regions using deep learning—progress and perspectives on drug discovery

Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery

Accurate Prediction of Antibody Function and Structure Using Bio-Inspired Antibody Language Model

Deep learning in modelling the protein–ligand interaction: new pathways in drug development

xTrimoABFold: De novo Antibody Structure Prediction without MSA

Precise Antigen-Antibody Structure Predictions Enhance Antibody Development with HelixFold-Multimer

AI-Based Protein Structure Prediction in Drug Discovery: Impacts and Challenges

Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions

Overview of AlphaFold2 and breakthroughs in overcoming its limitations

Structure-based, deep-learning models for protein-ligand binding affinity prediction

xTrimoABFold: Improving Antibody Structure Prediction without Multiple Sequence Alignments

AlphaFold-latest: revolutionizing protein structure prediction for comprehensive biomolecular insights and therapeutic advancements

Accurate prediction of CDR-H3 loop structures of antibodies with deep learning

Enhanced antibody-antigen structure prediction from molecular docking using AlphaFold2

AlphaFold2 in biomedical research: facilitating the development of diagnostic strategies for disease

Deep learning for protein structure prediction and design—progress and applications

Antibody Representation Learning for Drug Discovery

A Perspective on the Prospective Use of AI in Protein Structure Prediction

Inverse folding for antibody sequence design using deep learning

DLAB: deep learning methods for structure-based virtual screening of antibodies